

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Engineered pancreatic islets	<p>Engineered pancreatic islets could help lower rejection risk in patients with type 1 diabetes. Isolated mouse islets were engineered to display the fas ligand (TNF superfamily, member 6; FASL). In a mouse model of type 1 diabetes, the engineered islet grafts restored normal blood glucose levels. In mice receiving transplants, the engineered islet grafts survived beyond 500 days, whereas control grafts lacking FasL were rejected within 30 days. Next steps could include evaluating the engineered islets in additional diabetes models.</p> <p>SciBX 4(46); doi:10.1038/scibx.2011.1310 Published online Dec. 1, 2011</p>	Patent and licensing status unavailable	<p>Yolcu, E.S. <i>et al. J. Immunol.</i>; published online Nov. 7, 2011; doi:10.4049/jimmunol.1003266 Contact: Haval Shirwan, University of Louisville, Louisville, Ky. e-mail: haval.shirwan@louisville.edu Contact: Esma S. Yolcu, same affiliation as above e-mail: esma.yolcu@louisville.edu</p>